Welcome to our dedicated page for Accuray Incorporated news (Ticker: $ARAY), a resource for investors and traders seeking the latest updates and insights on Accuray Incorporated stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Accuray Incorporated's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Accuray Incorporated's position in the market.
Rhea-AI Summary
Accuray Incorporated (NASDAQ: ARAY) announced that the Providence Swedish Radiosurgery Center in Seattle, Washington is enhancing its cancer treatment capabilities with the purchase of the latest generation CyberKnife S7 System, the hospital's second CyberKnife radiation delivery device purchase. The precision and accuracy enabled by the system's robotic design will also make it an ideal choice for the treatment of neurologic disorders. The new system will enable the medical team to deliver gold standard stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT) treatments faster than with previous models, expanding access to an effective and convenient option to more patients. The CyberKnife S7 System is a non-invasive radiation therapy device that was built from the ground-up to provide clinicians with the speed they need for operational efficiency without sacrificing the precision and accuracy required for stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.36%
Tags
-
Rhea-AI Summary
Accuray Incorporated (NASDAQ: ARAY) will report financial results for the second quarter of fiscal year 2024, ended December 31, 2023, during a conference call on January 31, 2024. The conference call will be hosted by company management and a live webcast will be available. Investors can access the webcast replay from the Investor Relations section of the company's website. The dial-in numbers for the conference call and the replay numbers are provided for both USA and international participants.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Accuray Incorporated (NASDAQ: ARAY) has initiated sales of the VitalHold™ package supporting surface-guided radiation therapy (SGRT) on the Radixact® System in Japan. The VitalHold feature incorporates SGRT capability on the Radixact System using the Catalyst+ HD system manufactured by C-RAD, enabling medical teams to offer a wider range of radiotherapy treatment options using one device. This new feature will make it possible to deliver deep inspiration breath hold (DIBH) treatments, primarily for breast cancers, and perform markerless patient setup, reducing the burden on medical staff and patients. The introduction of the VitalHold package is a significant technological innovation for the Radixact System, enhancing its functionality and versatility in the Japanese market, where over 100 units are routinely used to treat cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.17%
Tags
Rhea-AI Summary
Accuray Incorporated (NASDAQ: ARAY) Achieves 8% Revenue Growth, Reiterates FY 2024 Guidance
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.56%
Tags
-
Rhea-AI Summary
Accuray Incorporated (NASDAQ: ARAY) will be participating in the 14th Annual Jefferies London Healthcare Conference on November 15th, 2023. The management team will present and participate in a Q&A session. The presentation will be available for live webcast on the company's Investor Relations section. A webcast replay will also be available on the company's website for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.38%
Tags
-
Rhea-AI Summary
Accuray Incorporated will report financial results for the first quarter of fiscal year 2024 on November 7, 2023. A conference call will be hosted by company management at 1:30 p.m. PT/4:30 p.m. ET. Dial-in numbers and webcast details are provided.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.53%
Tags
Rhea-AI Summary
Accuray's Tomo® C radiation therapy system receives approval in China, expanding access to radiotherapy treatments for cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.15%
Tags
-
Rhea-AI Summary
Accuray announces pending 510(k) for online adaptive therapy option, Cenos, for its Radixact System. Addition of Cenos allows online adaptation of treatment plan. Contouring portion of planning process automated by Limbus AI. Accuray committed to evolving radiation delivery systems. Partnership with Limbus AI praised. Accuray highlights include new financing options and VitalHold Breast Package now cleared. CyberKnife System offers advanced precision and real-time AI-driven treatment delivery.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.84%
Tags
-
Rhea-AI Summary
Accuray opens new global training facility in Madison, Wisconsin
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.73%
Tags
Rhea-AI Summary
Accuray to host discussion with analysts and investors at ASTRO Annual Meeting on October 3, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.21%
Tags
Accuray Incorporated
Nasdaq:ARAY
ARAY Rankings
ARAY Stock Data
160.65M
88.53M
3.58%
66.36%
5.31%
Surgical and Medical Instrument Manufacturing
Manufacturing
United States of America
MADISON
About ARAY
accuray incorporated (nasdaq: aray) is a radiation oncology company that develops, manufactures and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. the company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. for more information, please visit www.accuray.com. for career opportunities, please visit http://www.accuray.com/careers.